Aditxt (ADTX)

The company’s portfolio includes programs such as Adimune and AditxtScore. Adimune is associated with the development of immune-modulating therapies, including approaches intended to induce tolerance in areas such as organ transplantation and autoimmune disease. The goal of immune tolerance technology is to reduce unwanted immune attacks while avoiding broad, long-term immune suppression where possible. Aditxt has also described work around Apoptotic DNA Immunotherapy, including ADI-100, which is designed to mimic natural mechanisms the body uses to learn tolerance toward tissues.

AditxtScore focuses on immune monitoring. The program is intended to provide information about an individual’s immune status, helping to characterise immune responses in a more targeted way. Such tools are relevant in a healthcare landscape where diagnostics, personalised medicine, and treatment monitoring are increasingly important.

The company operates in a biopharmaceutical development environment that involves scientific uncertainty, regulatory review, clinical validation, and significant funding requirements. Its activities are concentrated on discovery and development rather than a broad commercial product base.

Aditxt is distinctive because it frames its strategy around both sides of immune-system management: measuring immune activity and developing ways to modulate it. Its work addresses areas where immune balance is central, including transplant medicine, autoimmune disorders, and broader applications in immune health.